The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 24 April 2007, www.theannals.com, DOI 10.1345/aph.1H460.
 The Annals of Pharmacotherapy: Vol. 41, No. 5, pp. 824-832. DOI 10.1345/aph.1H460
© 2007 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kleppinger, E. L
Right arrow Articles by Helms, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kleppinger, E. L
Right arrow Articles by Helms, K.

NEW DRUG DEVELOPMENTS

The Role of Vildagliptin in the Management of Type 2 Diabetes Mellitus

Erika L Kleppinger, PharmD BCPS CDE

Assistant Clinical Professor, Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Auburn, AL

Kristen Helms, PharmD

Assistant Clinical Professor, Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University

Reprints: Dr. Kleppinger, 1321 Walker Bldg., Auburn University, Auburn, AL 36849, fax 334/844-4410, kleppel{at}auburn.edu

OBJECTIVE: To highlight the role of incretin hormones in the management of type 2 diabetes mellitus with a focus on vildagliptin, a dipeptidyl peptidase IV (DPP IV) inhibitor currently in development.

DATA SOURCES: Searches were conducted in MEDLINE (1950-April 2007) and International Pharmaceutical Abstracts (1970-April 2007) using the key words vildagliptin, LAF237, and dipeptidyl peptidase IV inhibitor. Additional data were obtained from abstracts presented at the American Diabetes Association Scientific Sessions (2003-2006) and from the manufacturer.

STUDY SELECTION AND DATA EXTRACTION: Articles pertaining to the pharmacology, pharmacokinetics, safety, and efficacy of vildagliptin for the treatment of type 2 diabetes were reviewed for inclusion. When available, human trials were included over animal studies.

DATA SYNTHESIS: Reduced incretin effect is thought to be associated with type 2 diabetes. Glucagon-like peptide-1 (GLP-1), an incretin hormone, stimulates postprandial insulin release; however, it is rapidly degraded by DPP IV. Studies evaluating the use of vildagliptin in patients with type 2 diabetes found significant decreases in DPP IV and increased GLP-1 activity 45 minutes after dosing. Glucagon levels were reduced, with little to no change in insulin levels. With vildagliptin doses ranging from 25 mg daily to 100 mg twice daily, researchers observed consistent reductions in fasting plasma glucose, 4 hour postprandial glucose, and hemoglobin A1c. Similar benefits were seen when vildagliptin was used in combination with metformin. Vildagliptin was well tolerated after 12 weeks; however, incidences of hypoglycemia increased with longer study duration. Optimal results with minimal adverse effects were achieved with 25 mg twice daily and 50 mg once daily doses.

CONCLUSIONS: Vildagliptin represents a safe and effective new approach to targeting GLP-1 deficiencies in patients with type 2 diabetes by inhibiting DPP IV.

Key Words: dipeptidyl peptidase IV inhibitor, LAF237, type 2 diabetes mellitus, vildagliptin

Published Online, April 24, 2007. www.theannals.com, DOI 10.1345/aph.1H460

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-07-013-H01




homecopy help contact us subscription past issues search current issue
Copyright © 2007 by Harvey Whitney Books Company.